Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for APNHY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for APNHY and 80,000+ other tickers.
See exactly how APNHY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for APNHY and 80,000+ other tickers.
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counter medicines under the Emla, Maltofer, Ovestin…
Aspen Pharmacare Holdings Limited (APNHY) Shareholder/Analyst Call Prepared Remarks Transcript
Aspen Pharmacare Holdings Limited (APNHY) Q2 2026 Earnings Call Transcript
Aspen Pharmacare's unbranded version of Novo Nordisk's popular diabetes drug Ozempic could be registered in Canada in the second or third quarter of this year, the South African pharmacueticals group's CEO said on Tuesday.
Aspen Pharmacare Holdings Limited (APNHY) Discusses Proposed Divestment of APAC Operations Excluding China Transcript
Aspen Pharmacare Holdings Limited (OTCPK:APNHY) Q4 2025 Earnings Call September 4, 2025 2:30 AM EDT Company Participants Sanelisiwe Tonga Stephen Saad - Group CEO & Executive Director Sean Capazorio - Group CFO & Executive Director Presentation Sanelisiwe Tonga Good morning, ladies and gentlemen. A very warm welcome to Aspen's 2025 Annual Results Presentation.